Healthcare · Drug Manufacturers - Specialty & Generic
Made onAug 18, 2026
Price at call$508.48
6-month call Bear -5.0%
Target by Feb 2027$483.00
Great value below$425.00
Modelv0.6.0
Projection vs Actual
(6M history + forecast)
The masterbrain's trajectory (blue, curved through its 7 checkpoints), the deterministic v0.3 control (dashed), and the actual price (green) overlaid from the prediction date forward.
Forecast Change-5.0% to $483.00
Predicted High$506.00in 2 weeks
Predicted Low$483.00at 6 months
Max Drawdown (predicted)-5.0%
Forecast
The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded.
Predicted Aug 18, 2026 3:07 am
Bear
UTHR trends lower to
$483.00
(-5.0% from $508.48)
by Feb 2027.
decay
ThesisUTHR trades slightly above composite fair value with low beta and no near-term catalysts; expect drift lower toward the $479 anchor before stabilizing, with the moonshot narrative providing a soft floor around DCF value.
Invalidated ifBreak above $535 on Tyvaso volume acceleration or Miromatrix milestone; conversely break below $455 invalidates the floor thesis.
Checkpointtime after the call
Datewhen it gets graded
Predictedthe claim: closing price
Current priceactual close — fills in over time
Predicted returnpredicted vs $508.48 at call
Conv.brain's confidence, 1–10
Driverwhy the brain put the point here
Prediction made
Aug 18, 2026
—
$508.48at call
—
—
The anchor — every point below is measured from this price and date.
2 weeks
Sep 1, 2026
$488.38–$528.58typical range · internal point $506.00
—
±4.0%
6/10
Low-vol drift, no catalyst, slight mean reversion
What actually happened:
closed $512.70
on Sep 1, 2026 = +0.8% vs the call
(predicted -0.5%)
· direction HIT
(called flat, was flat)
· off by 1.3 pp
· accuracy 10/10
· typical range ±4.0%:
inside the band
· S&P -0.8%
over the same window — beat it
1 month
Sep 18, 2026
$479.35–$537.61typical range · internal point $501.50
—
±5.7%
6/10
Value gravity begins pulling toward composite fair value
What actually happened:
closed $497.27
on Sep 17, 2026 = -2.2% vs the call
(predicted -1.4%)
· direction HIT
(called flat, was flat)
· off by 0.8 pp
· accuracy 10/10
· typical range ±5.7%:
inside the band
· S&P -0.7%
over the same window — beat it
Year-end positioning, tax loss avoided given flat return
5 months
Jan 18, 2027
$485.00
—
-4.6%
3/10
Converges toward signal-adjusted fair value anchor
6 months
Feb 18, 2027
$483.00
—
-5.0%
3/10
Settles near composite FV, pipeline optionality holds floor
Why ranges on the short rungs?
A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here —
three prompt formulations all lost to simply predicting zero — while the stock's own
volatility scale (σ×√t) described those windows well. So the short rungs claim what's
actually knowable: the typical travel, with earnings timing flagged where the variance
will come from. The internal point calls keep being generated and graded to map where
real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.
Deterministic control (v0.3 value line) targets
$512.69
(+0.8%)
— both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it.
Brain: claude-opus-4-7.
Weaknesses
No weaknesses recorded for this run.
All inputs present, no fallbacks used — nothing to flag.
Equation Inputs
Everything feeding the v0.6.0 model — value anchors, the stock's own price behaviour, and the tunable knobs.
Value anchors (from deep analysis)
Price at call
$508.48
Composite fair value
$479.59
Signal-adjusted fair value
$485.47
DCF fair value
$464.12
Anchored-PE fair value
$659.03
Buy-below (value lens)
$425.00
Value net score
-28
Value confidence
7 / 10
Quality net score
+63
Memo confidence
7 / 10
Deserved value (base)
—
Quality tilt
—
Deserved value (used)
—
Coherence (value × quality)
—
Price behaviour (trailing — shapes the realism line)